Here it is........Sydney, Australia 15th October 2012 – The...

Here it is........

Sydney, Australia 15th October 2012 – The Board of NuSep (ASX:NSP) wishes to advise the
market that it has resolved, subject to shareholder approval, to spin out its therapeutic plasma
fractionation business, called PrIME Biologics.
PrIME Biologics is using NuSep’s PrIME Technology in its therapeutic plasma manufacturing
process. NuSep, by comparison, is the developer of the PrIME Technology. NuSep’s strategy is
to develop applications of the PrIME Technology which will generate sales of both equipment
and long term supply contracts of the consumables. It is PrIME Biologics’s goal to open up the
Asian therapeutic plasma market and particularly the untapped Currently Unprocessable Plasma
(CUP) market. The goals and business plans for both companies are significantly different and
require significantly different operational focus.
For this reason the Board believes that NuSep’s overall goal of ‘Becoming the leading supplier in
the BioSeparations market’ is best served by having successful applications of its PrIME
Technology operating as separate independent companies. NuSep is then able to concentrate on
commercialising other applications of the PrIME Technology including IVF sperm separation,
recombinant proteins and renal dialysis to name a few.
Further, it has been difficult to finalise the external funding for PrIME Biologics while it formed
part of the NuSep group as NuSep has a market capitalisation of less than A$10m relative to the
S$60m (A$46m) valuation of PrIME Biologics. By spinning out PrIME Biologics the issue of
PrIME funding will be addressed.
Recent PrIME Developments
Over the last six months PrIME has achieved a number of critical milestones. Specifically PrIME
has:
• Signed a HOA to supply CUP products to India;
• Completed the purchase of a cGMP1 facility in Singapore valuing PrIME at S$60m
(A$46m);
• Is drawing down its first Singapore Government loan instalment; and
• Installing the pilot scale PrIME production unit into PrIME’s Singapore cGMP facility.
Terms of the Proposed Spin Out
The current share capital of PrIME Biologics is held 90% by NuSep and 10% by Luye Pharma
Group. At the time of the IPO the capital structure of PrIME is expected to look like:
1 cGMP is current Good Manufacturing Practise
– 2 –
Luye Pharma Group 20%
Investor Group 10%
Escrow NuSep Shareholders 50%
NuSep 10%
IPO 10%
Total 100%
All of the funds raised from the sale of the PrIME Biologics shares will be retained in PrIME
Biologics and will be used to produce the first registered therapeutic product using the PrIME
Technology. NuSep will retain 10% of the shares in PrIME Biologics as a long term investment.
As part of the spin off of PrIME Biologics it is proposed that all of the ordinary fully paid escrow
shares be distributed pro rata to NuSep Shareholders on a 1 for 5 basis. The result of the pro rata
distribution would be that after the distribution, every Shareholder will also hold 1 PrIME
Biologics Share for every 5 Shares held in the capital of NuSep Holdings Ltd. No payment is
required from Shareholders for this distribution as the spin out is defined to be a return of
capital.
The escrow shares that are to be distributed to shareholders will represent 50% of PrIME
Biologics at the time of the spin out. NuSep will sell 10% of PrIME Biologics shares in
March/April 2013 under an IPO prospectus. All of the funds raised, excluding costs, in the IPO
will be retained by PrIME Biologics. Post this IPO NuSep will still hold 10% of PrIME
Biologics.
The proposed spin out will be achieved by way of an ordinary shareholder resolution approving
an equal reduction of capital under Section 265C of the Corporations Act. NuSep will put this
resolution to the 2012 Annual General Meeting to be held on 30 November 2012.
Indicative Timetable for the Spin Out
While a final timetable has not been finalised, below is an indicative timetable:
Date Event
15 October 2012 Announcement of PrIME Biologics Spin Out.
30 October 2012 Notice of Meeting sent to shareholders incorporating the Spin Out
resolution.
30 November 2012 AGM to approve the PrIME Spin Out.
31 January 2013 NuSep Shareholders entitlement date to the PrIME Biologics shares.
6 February 2013 PrIME Biologics posts shareholder statements to all shareholders.
7 February 2013 PrIME Biologics posts prospectus to all PrIME Biologics shareholders
and other investors.
Early April 2013 PrIME Biologics capital raising closes.
Early May 2013 PrIME Biologics lists on the ASX.
30 November 2013 All the escrow shares become fully tradable.
– 3 –
Impact on NuSep
The spin out of PrIME Biologics from NuSep is a significant event as it represents the first
commercial application of the PrIME Technology. Post the spin out, the relationship with PrIME
Biologics will be one of supplier/customer. As part of its decision to approve the spin out the
Board of NuSep has considered a number of other factors including the financial impact on
NuSep’s Balance Sheet/P&L and the future growth of NuSep. These items are addressed in more
detail below.
Impact on the Balance Sheet and P&L
The spin out of PrIME Biologics from NuSep will not have any significant impact on NuSep’s 30
June 2012 Balance Sheet as NuSep did not at that time have any PrIME Biologics assets of
material value on its Balance Sheet.
More importantly, post the spin out, NuSep will no longer incur any expenditure associated with
PrIME Biologics. To put this expenditure into perspective, during the 2011-12 financial year
NuSep incurred over $400,000 in PrIME Biologics expenditure. This expenditure was
incorporated into the Company’s P&L and formed part of the $1,128,774 EBITDA loss. From the
2013-14 financial year onwards, NuSep will not incur any PrIME expenditure in its P&L.
Impact on NuSep’s Future Growth
While the expenditure side is important, the spin out will create two new revenue streams for
NuSep. These are:
• PrIME Equipment sales
PrIME Biologics will acquire all of its PrIME equipment from NuSep. The first purchase
relating to the Singapore production unit will generate sales of approximately $850,000 to
NuSep. NuSep will be PrIME Biologics sole supplier of PrIME Technology for these new
facilities.
• PrIME Consumable sales
PrIME Biologics will purchase under a long term exclusive contract the PrIME
consumables from NuSep. This will generate ~ $3-4m pa in sales to NuSep once the
PrIME Biologics plant in Singapore is at full capacity. Each new plant that PrIME
Biologics establishes thereafter will generate similar amounts of both equipment and
consumables sales.
The net result of the spin out for NuSep is:
• Reduced expenditure; and
• Two new highly profitable revenue streams.
In summary, the spin out of PrIME Biologics enables NuSep to focus on development of new
PrIME Technology applications (IVF, Recombinant and Dialysis) while generating the first of a
series of unique high margin revenue streams.
**